Get started

Tsxv

$NRX.V Outpaces Biotech Peers Following TSX.V Listing The biotech sector is presenting exciting opportunities for investors despite the broader downturn in global equity markets. Many of the best biotech companies and ETFs have both strong drug candidate pipelines in the works as well as winning drugs and therapeutic products already on the market. The COVID-19 pandemic has proven and created massive opportunities for the biotechnology sector as a whole, particularly so around innovative players that are developing therapeutic solutions with disruptive potential. One new player to the field is Nurexone Biologic (NRX.V), a new listee on the TSXV exchange that is redefining exosome therapeutics for application to traumatic brain and spinal cord injuries. It is creating a platform for biologically-guided ExoTherapy that will be administered minimally invasively to patients who have had catastrophic spinal cord injuries. Since July 15th, NRX +26% as it attracts new investors and institutional players begin to trade the equity. In comparison, the TSX/SPX composite index charted 6% gains, indicating that NRX far outperformed the market baseline over the course of the summer rally. Relative to sectoral ETFs, Nurexone is also trading strong. IBBQ is +6.9% and XBI +6% over the same timeframe NRX is +26%; it is important to note that over this period, the company did not release any price sensitive announcements that would otherwise account for its significant bullish price movement. Further, exosome-based equities are one area of the wider biotech industry that has continuously traded robustly despite subpar performance for equity markets this year. Sectoral competitors are mixed bag, with KMPH +4.8% while APTO is down 4.4%. Kodiak Biosciences (KOD) jumped 20%, though it still lags behind NRX's 26% increase. This indicates that as exosome therapeutic developers struggle to maintain forward momentum amidst the backdrop of a challenging macroeconomic landscape, NRX is outperforming both sectoral ETFs and direct competitors. Though its a newby to capital markets, so far Nurexone is standing out as the bullish outlier with LT potential.
TSXV:NRX
by BiotechBrandon
NLC.V High Flag Volume Contraction into CatalystsNLC has been digesting its big move up over the past couple weeks. It is setting up beautifully in a flag with noted volume contracting and price tightening up. We are in what should be a busy month + for NLC with DFS due out within the next couple weeks + a US senior exchange uplisting. Keep an eye out for CATL, (I cant post a link in the text as im not on a pro sub) but they raised 9 billion through a share offering to finance a range of projects. One of which is likely Neo Lithiums 3Q project. NLC leadership did a heck of a job raising capital last January over $3 CDN. They will likely be able to get another great deal in this price range as well. Likely something at the market funded by CATL + the uplisting + the brine mine starting up production near year end gives NLC some juice to move up over $5 CDN and more throughout the end of the year. LAC.TO has been running lately, I find tracking a couple lithium miners helps give perspective to the market. NLC momentum built through august was pretty much handed off to LAC through sept. Of course the two aren't that connected but there are traders in every market, If lithium stocks hold and LAC hit selling pressure traders may come back to NLC and bid up the stock further on news. Just some thoughts to consider, always do your own DD and follow your own trading rules. I own shares in NLC.V Cheers, Luke
NLong
by LeBelleChart
Drawn trendline + LR on QuisCharts are an amazing tool. Been an amazing 1.5 years having control of my money to learn about technical analysis. I have been meaning to take a look at quis technically on this uptrend, Linear Regression I find is a great tool to price gain further context on longer time frames. I started this chart by inputting my own support and resistance trend lines. It follows that as you map out a line acting as resistance and one as support, you are going to find alot of the stocks price action in between. This price action acts as data to be inputted into a Linear Regression model. Utilizing 3 regression lines set from Standard Deviations -3 to +3, we capture 99.7% of data-price, for Quis. Quis over the past week has again started tightening up. Trading well below its daily average today into last weeks session. I have to admit I was off on the last tighten up around earnings. stock slipped up and went the other way for a week. these weeks candles and volume will be very telling to me on Quis being ready to go. Catalysts on the near term horizon include Visa end point certification for LedgerPay. LedgerPay is the first payment processing solution that is built on cloud technology, Microsofts Azure Cloud to be specific. You may have seen news out that Amazon is looking to build its own payment platform for retail business. Its to be able to take in all the data on AWS network and make AWS more valuable. Microsoft in a battle forever now on cloud with Amazon got here first by working with Quisitive, a premier partner of microsoft. Microsoft expects to punch back here with Quis as its boxer, this is due to the product offering and funcationality of Ledgerpay and its data intelligence arm and those capabilities. Further to certification, I think a contract being landed (guidance given on last earnings call Q&A that customers for Ledgerpay would likely be signing contracts before or shortly after LP is fully commercialized with Visa end point cert. It is on news of these contracts I feel the stock can push up to an area in the +2-+3 SD Channel. CEO Mike Reinhart represented Quis on an gateway investor webinar last week and guided that an uplist in Canada to the TSX was foundationally in place, and that US uplist was near as well. $QUISF currently trade on the pinks OTC. Quis also just filed an updated and amended SBP, as i note in my DD pieces, dilution is part of the game here and a risk to upside movement. Given the last two raises made by quis came after moves up, I think it follows that this will will too, but that may not align with acquisition opportunity forcing it to come earlier. In any case please always do your DD, feel free to check out my substack lebellechart for my own DD, and follow your own trading & investing rules. Cheers, Luke
TSXV:QUISLong
by LeBelleChart
Quisitive Technology Solutions TA and thoughts $QUIS.VQuisitive $QUIS.V / $QUISF will report Q2 earnings on Aug 30th after the bell. This will be a company changing quarterly report IMO. For a detailed breakdown on what to expect for earnings you can follow my substack, I will be publishing an updated Q2 projection this weekend. Price has failed to break lower on the last two selloffs. the 200 dma held and the stock bounced up Friday on light volume. Take in that volume contraction over August. Besides a few large buys that show up its been quiet on the Quis front. I believe Quis will run into earnings now this week. Its not going to take a whole lot to get us up to that overhead resistance I have lined out (1.68-1.70 range). This move up implies just over a 20% gain in 6 trading days. Where the fun/risk comes into play is the market reaction to the numbers Quis puts up. IMO there is a chance Quis can push upwards of $24 million in revenue, which would be near 100% yoy growth. Again, my stack will breakdown this down in more detail. Furthermore what will drive sentiment is comments from CEO Mike Reinhart on LedgerPay commercialization being on schedule (no reason to believe it wont be) + any pilot projects that have been undertaken during Q3. Full Commercialization for LedgerPay is due after Visa Certification has been awarded, expected at end of Sept. All in all, I believe there is a trade to be had here, as well as a good buy range at the start of the week for a long position. I also have quis's chart on stockcharts set up on weekly with rsi, macd and OBV - the stock is technically oversold and has a reasonably long runway if it moves up with purpose. I believe it will. Earnings could be the set up for a stronger push up near end of Sept when LP reaches full commercialization. Again, Mike Reinhart's comments will be key here to giving the market guidance. I have a large position relative to my book in $QUIS.V, As always please do your own DD and follow your own trading rules. Cheers, Luke
TSXV:QUISLong
by LeBelleChart
$JK.V Recharging to attack ATH againTSXV:JK may be recharging to make another attack at its all time high. We’re recently hit a new ATH with $JK.V as it broke through to a new high of $2.02 on its latest run. Taking a look at it’s current channels - both down and upward - along with the MACD and RSI it looks like we could be in for a retrace back down to the 0.618 of our local fractal @ 1.48, if not a little bit lower (0.786 ??), but ideally crossing dynamic channel supports that intersect with the 0.618 will provide a spring off point. It would be worth keeping an eye on this one over the next few days to prepare for an entry once support has been found and a bounce has started. Keep in mind that 1.34 could prove a good entry as well if the price decides to head that low. 
 A few points worth mentioning: - RSI is on the higher end, just leaving a VERY over bought state. - MACD is showing that bullish momentum has eased off and may flip into a bearish state soon.

 * This Content is for informational purposes only. You should not construe any such information or other material as investment, financial, or other advice.
JLong
by Magic-Charts
Just Kitchen - $JK.V : TSXV- 2 possible upcoming plays.This chart doesn’t have a lot of history, but if you start to look at it there are a few support and resistance points that are starting to get established. Using these as guidance I’m proposing two possible plays for Just Kitchen depending on the direction it chooses to travel in the coming days. As this is currently trading on very low volume, the measurements are long term goals and profits should be taken at key support and resistance levels to remain safe. I’ll be keeping my eyes open for directional travel with in the long/short entry zones to see how things start to play out.
J
by Magic-Charts
1
Quisitive Technology Solutions TA and thoughts $QUIS.VHey Folks, Quisitive won Microsoft's Healthcare Partner of the year award today. This was made possible by Quisitive acquiring MazikGlobal which was a premier partner of Microsoft prior to; they were (Quis is) considered "Partner 0" in Healthcare for Microsoft. In addition to LedgerPay Bank Sponsorship being announced, Quisitive has some stuff going for it. It has been getting strong PT upgrades. I think it is one worth watching over the next week to see how it behaves around entry into -3SD data territory. Regression to the mean is our friend here if you are long. Buyers matching sellers for some tight action over a couple days could set that up. Eyes on Volume. If Quis slips into that last channel I believe It will present a great buying opportunity for a long add. I have a Limit buy in for $1.48 to catch any weakness tmrw on the open, adding to my own position. Please note I had links to the stated accomplishments (award and PT) but TV wont let me publish the idea with links in the notes here. I used yahoo finance and tipranks to source those pages. You can find them across other sites as well. Please do your own DD and follow your own trading rules. All the best, Luke
TSXV:QUISLong
by LeBelleChart
CloudMD $DOC.V - Months of selling and consolidation done?CloudMD has been under selling pressure for months now. Today it closed its Vision Pros Acquisition and is expected to close its largest acquisition - Oncidium this month as well. The company can boast a 125-130mil revenue run rate. Vision Pros adds 22 mil in rev and 10% EBITDA margins to the bottom line for CloudMD. I have a position in this company. It has not been an easy 3-4 months. The rest of the week will prove out if this was a one and done green day yesterday or if buyers are serious and ready to take control again. PT on DOC is $3.96. Was a "top pick" on Bloomberg MarketCall June 23rd. At some point the market is going to start respecting that revenue and positive EBITDA that the company is set to report for this full fiscal year. currently trading at 3x sales. This should definitely be on the watchlist now. Look to see Buyers control Price around the 2SD Cross as highlighted. DCA approach the play here. DOC.V is a long hold for myself. Hope the chart and thoughts help. Please do you own DD and follow your own trading rules. Cheers, Luke
DLong
by LeBelleChart
3
$NLC.V Potential breakout underway after Positive NR on Li MineNEO Lithium has been battling the last couple months. Great opp to buy the dip in mid may as I shared on Twitter/Substack. Today they released information updating the amount of High/Medium grade Li available at their Brine Mine location in the Lithium Triangle. NLC can now claim to hold one of the world's largest Li resources. They also have some of the highest test/quality Li. Arrow indicates how the mean price acted as resistance just last week. So I see that as an area of Significance over the next couple days/week for buyers to control price at this range. Volume will be key here as well. If NLC fails to crack, look to see if it can hold the upwards new trendline and/or 9 day ma. VWAP anchored from the high also shows that buyers are in control as we are trading above it. Look for continued curving of the VWAP to the upside. Catalysts yet to come for NLC later this Summer are the publication of the DFS and a potential offtake agreement with CATL, or financing from another partner downstream. I have a long position in NLC. Please do your own DD and follow your trading rules. Cheers, Luke
NLong
by LeBelleChart